Vanguard Capital Management
JUNS

Vanguard Capital Management’s Jupiter Neurosciences JUNS Stock Holding History

Vanguard Capital Management’s Portfolio JUNS Stock Details JUNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.4K Sell
1,707
-3,092
-64% -$73.1K ﹤0.01% 3991
2026
Q1 		$135K Buy
+4,799
New +$221K ﹤0.01% 3837

Other funds holding JUNS

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
SG
StoneX Group New York $2.48B AUM 33.54% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
LFAS
Level Four Advisory Services Dallas, Texas $3.54B AUM 37.12% 1-Year Est. Return
VC
Vestor Capital Chicago, Illinois $1.59M AUM 51.04% 1-Year Est. Return

Vanguard Capital Management's JUNS Position: Q2 2026 in Review

Vanguard Capital Management reduced its Jupiter Neurosciences (JUNS) stake by 64% in Q2 2026, selling an estimated $73.1K and leaving 1,707 shares worth $27.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3991.

Vanguard Capital Management first reported a position in JUNS in Q1 2026 and has held it in 2 quarters since. The position peaked at $135K in Q1 2026. 13 funds tracked by Wall St. Rank hold JUNS as of Q2 2026.

  • Vanguard Capital Management held 1,707 shares of Jupiter Neurosciences worth $27.4K as of Q2 2026.
  • Vanguard Capital Management sold 3,092 Jupiter Neurosciences shares in Q2 2026, an estimated $73.1K.
  • Jupiter Neurosciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3991 holding.
  • Vanguard Capital Management first reported a position in Jupiter Neurosciences in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Jupiter Neurosciences position peaked at $135K in Q1 2026.
  • 13 funds tracked by Wall St. Rank held Jupiter Neurosciences as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.